Relay Total Cash From Financing Activities from 2010 to 2024

RLAY Stock  USD 7.50  0.36  4.58%   
Relay Therapeutics Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities will likely drop to about 33 M in 2024. During the period from 2010 to 2024, Relay Therapeutics Total Cash From Financing Activities regression line of annual values had r-squared of  0.38 and arithmetic mean of  315,508,757. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2019-03-31
Previous Quarter
48.9 M
Current Value
1.5 M
Quarterly Volatility
128.9 M
 
Covid
Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 32.6 M, Interest Income of 32.6 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 50.19, Dividend Yield of 0.0 or PTB Ratio of 1.0. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Latest Relay Therapeutics' Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Relay Therapeutics over the last few years. It is Relay Therapeutics' Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
       Timeline  

Relay Total Cash From Financing Activities Regression Statistics

Arithmetic Mean315,508,757
Geometric Mean210,816,919
Coefficient Of Variation48.64
Mean Deviation119,833,424
Median394,972,000
Standard Deviation153,469,422
Sample Variance23552.9T
Range420.9M
R-Value(0.62)
Mean Square Error15697.5T
R-Squared0.38
Significance0.01
Slope(21,185,606)
Total Sum of Squares329740.1T

Relay Total Cash From Financing Activities History

202433 M
202334.8 M
2022289.9 M
2021388.1 M
2020426.5 M
20195.6 M

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities34.8 M33 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.